Bifogade filer
20251117 ViroGates Comp Ann 18 Directed Issue
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Company Announcement no. 18/2025 (November 17, 2025)
BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, announces that the Company at a board of directors meeting today have decided to seek to strengthen its capital position by initiating a directed share offering to a limited number of potential investors without pre-emptive rights for the existing shareholders aiming at raising gross proceeds in cash of between DKK 18 million and DKK 20 million.
The board has received indications from investors and expects to offer and issue up to 1,547,412 new shares with a nominal value of DKK 1.00 each, which – if fully subscribed for – will result in an increase in the share capital of the Company by nom. DKK 1,547,412. The new shares will be issued pursuant to an authority vested in the board according to Section 2.3 and 2.3.1. of the Articles of Association of ViroGates A/S.
The current share capital of ViroGates A/S amounts to nominally DKK 7.737.064 divided into 7.737.064 shares with a nominal value of DKK 1.00 each, and with the same number of voting rights.
The new shares shall be subscribed for at market price, which will be established as the closing price for the shares trading at the Nasdaq First North Growth Market in Copenhagen on 17 November 2025.
The new shares will carry the same rights pursuant to the Company’s Articles of Association. Furthermore, the new shares will be issued in the existing ISIN code DK0061030574.
The proceeds from the directed issue, if completed, will be used by the Company to strengthen its cash and equity position, secure the necessary working capital and the ability of the Company to execute its strategy of offering quality diagnostic products to serve the Longevity and Healthcare market.
This message is also available here
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical diagnostics company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ salesforce covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.